2009

1. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

   Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410